Early mortality and cause of deaths in patients using HAART in Brazil and the United States

被引:58
作者
Grinsztejn, Beatriz [1 ]
Veloso, Valdilea G.
Friedman, Ruth K.
Moreira, Ronaldo I.
Luz, Paula M.
Campos, Dayse P.
Pilotto, Jose H.
Cardoso, Sandra W.
Keruly, Jeanne C. [2 ]
Moore, Richard D. [2 ]
机构
[1] Inst Pesquisa Clin Evandro Chagas, Fundacao Oswaldo Cruz, Lab Pesquisa Clin DST & AIDS, BR-21045900 Rio De Janeiro, Brazil
[2] Johns Hopkins Univ, Dept Med, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
antiretroviral therapy; causes of death; cohort; early mortality; HIV/AIDS; ACTIVE ANTIRETROVIRAL THERAPY; IMMUNE RECONSTITUTION DISEASE; RIO-DE-JANEIRO; SOUTH-AFRICA; HIV-1-INFECTED PATIENTS; TREATMENT PROGRAM; HIV-INFECTION; TUBERCULOSIS; ADULTS; AIDS;
D O I
10.1097/QAD.0b013e32832ec494
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To compare the early mortality pattern and causes of death among patients starting HAART in Brazil and the United States. Methods: We analyzed the combined data from two clinical cohorts followed at the Johns Hopkins AIDS Service in Baltimore, United States, and the Evandro Chagas Clinical Research Institute AIDS Clinic in Rio de Janeiro, Brazil. Participants included those who entered either cohort between 1999 and 2007 and were antiretroviral naive. Follow-up was at 1 year since HAART initiation. Cox proportional hazards regression analysis was used to assess the role of the city on the risk of death. Results: A total of 859 and 915 participants from Baltimore and Rio de Janeiro, respectively, were included. In Rio de Janeiro, 64.7% of deaths occurred within 90 days of HAART initiation; in Baltimore, 48.9% occurred between 180 and 365 days. AIDS-defining illness (61.8%) and non-AIDS-defining illness (55.6%) predominated as causes of death in Rio de Janeiro and Baltimore, respectively. Risk of death was similar in both cities (hazard ratio 1.04; P value=0.95) after adjusting for CD4(+) T cell count, age, sex, HIV risk group, prior AIDS-defining illness, and Pneumocystis jirovecii pneumonia and Mycobacterium avium prophylaxis. Individuals with CD4+ T cell count less than or equal to 50cells/mu l (hazard ratio 4.36; P=0.001) or older (hazard ratio, 1.03; P=0.03) were more likely to die. Conclusion: Although late HIV diagnosis is a problem both in developed and developing countries, differences in the timing and causes of deaths clearly indicate that, besides interventions for early HIV diagnosis, different strategies to curb early mortality need to be tailored in each country. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
引用
收藏
页码:2107 / 2114
页数:8
相关论文
共 31 条
  • [1] Allison PD., 2010, Survival Analysis Using SAS: A Practical Guide
  • [2] [Anonymous], 2009, 16 C RETR OPP INF MO
  • [3] Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2
  • [4] Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003
    Campos, DP
    Ribeiro, SR
    Grinsztejn, B
    Veloso, VG
    Valente, JG
    Bastos, FI
    Morgado, MG
    Gadelha, AJ
    [J]. AIDS, 2005, 19 : S22 - S26
  • [5] CAMPOS DP, 2006, 10 C INF HLTH FLOR
  • [6] Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa
    Coetzee, D
    Hildebrand, K
    Boulle, A
    Maartens, G
    Louis, F
    Labatala, V
    Reuter, H
    Ntwana, N
    Goemaere, E
    [J]. AIDS, 2004, 18 (06) : 887 - 895
  • [7] Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010
  • [8] Determinants of disease presentation and outcome during cryptococcosis:: The CryptoA/D study
    Dromer, Francoise
    Mathoulin-Pelissier, Simone
    Launay, Odile
    Lortholary, Olivier
    [J]. PLOS MEDICINE, 2007, 4 (02) : 297 - 308
  • [9] Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies
    Egger, M
    May, M
    Chêne, G
    Phillips, AN
    Ledergerber, B
    Dabis, F
    Costagliola, D
    Monforte, AD
    de Wolf, F
    Reiss, P
    Lundgren, JD
    Justice, AC
    Staszewski, S
    Leport, C
    Hogg, RS
    Sabin, CA
    Gill, MJ
    Salzberger, B
    Sterne, JAC
    [J]. LANCET, 2002, 360 (9327) : 119 - 129
  • [10] Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal:: a 7-year cohort study
    Etard, JF
    Ndiaye, I
    Thierry-Mieg, M
    Guèye, NFN
    Guèye, PM
    Lanièce, I
    Dieng, AB
    Diouf, A
    Laurent, C
    Mboup, S
    Sow, PS
    Delaporte, E
    [J]. AIDS, 2006, 20 (08) : 1181 - 1189